GEN-PIROXICAM - CAP 20MG CAPSULE

Nazione: Canada

Lingua: inglese

Fonte: Health Canada

Principio attivo:

PIROXICAM

Commercializzato da:

GENPHARM ULC

Codice ATC:

M01AC01

INN (Nome Internazionale):

PIROXICAM

Dosaggio:

20MG

Forma farmaceutica:

CAPSULE

Composizione:

PIROXICAM 20MG

Via di somministrazione:

ORAL

Confezione:

100/500

Tipo di ricetta:

Prescription

Area terapeutica:

OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS

Dettagli prodotto:

Active ingredient group (AIG) number: 0114612001; AHFS:

Stato dell'autorizzazione:

CANCELLED POST MARKET

Data dell'autorizzazione:

2010-08-04

Scheda tecnica

_ _
_ _
_Page 1 of 35_
PRODUCT MONOGRAPH
PR
GEN-PIROXICAM
(Piroxicam, USP)
10 and 20 mg Capsules
Nonsteroidal Anti-inflammatory Drug (NSAID)
Genpharm ULC
85 Advance Road
Etobicoke, ON
Canada
M8Z 2S6
DATE OF REVISION:
December 01, 2009
CONTROL NO: 129679
_ _
_ _
_Page 2 of 35_
Table of Contents
PART I: HEALTH PROFESSIONAL
INFORMATION.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL
USE..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND
PRECAUTIONS..................................................................................5
ADVERSE
REACTIONS..................................................................................................14
DRUG INTERACTIONS
..................................................................................................19
DOSAGE AND
ADMINISTRATION..............................................................................22
OVERDOSAGE
................................................................................................................24
ACTION AND CLINICAL PHARMACOLOGY
............................................................24
STORAGE AND
STABILITY..........................................................................................25
SPECIAL HANDLING INSTRUCTIONS
.......................................................................25
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................25
PART II: SCIENTIFIC INFORMATION
...............................................................................27
PHARMACEUTICAL
INFORMATION..........................................................................27
CLINICAL
TRIALS..........................................................................................................27
DETAIL